Novavax (NVAX) Accumulated Depreciation & Amortization: 2011-2024
- Novavax's Accumulated Depreciation & Amortization fell 34.43% to $49.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $197.2 million, marking a year-over-year increase of 18.91%. This contributed to the annual value of $48.0 million for FY2024, which is 17.07% up from last year.
- Per Novavax's latest filing, its Accumulated Depreciation & Amortization stood at $49.2 million for Q4 2024, which was down 34.43% from $75.0 million recorded in Q4 2023.
- Novavax's Accumulated Depreciation & Amortization's 5-year high stood at $75.0 million during Q4 2023, with a 5-year trough of $17.8 million in Q4 2020.
- For the 3-year period, Novavax's Accumulated Depreciation & Amortization averaged around $57.1 million, with its median value being $49.2 million (2024).
- In the last 5 years, Novavax's Accumulated Depreciation & Amortization skyrocketed by 83.31% in 2022 and then crashed by 34.43% in 2024.
- Over the past 5 years, Novavax's Accumulated Depreciation & Amortization (Quarterly) stood at $17.8 million in 2020, then spiked by 45.00% to $25.8 million in 2021, then skyrocketed by 83.31% to $47.3 million in 2022, then soared by 58.52% to $75.0 million in 2023, then slumped by 34.43% to $49.2 million in 2024.
- Its Accumulated Depreciation & Amortization was $49.2 million in Q4 2024, compared to $75.0 million in Q4 2023 and $47.3 million in Q4 2022.
